How many studies have been conducted on Afatinib?

BiohacksAI has indexed 297 PubMed studies on Afatinib, including 29 randomized controlled trials (RCTs). 76% of studies involve human subjects.

What are the main research areas for Afatinib?

The primary research domains for Afatinib are 🔬 Oncology, 🫘 Kidney, ⏳ Longevity & Aging. This is based on analysis of 297 PubMed studies using the BiohacksAI evidence platform.

Afatinib

A quinazoline and butenamide derivative that acts as a tyrosine kinase inhibitor of epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of metastatic NON-SMALL CELL LUNG CANCER.

297+ PubMed studies analyzed · 29 RCTs · Evidence Score: 53.6

Research Domains

Afatinib has been studied across 10 research domains including 🔬 Oncology, 🫘 Kidney, ⏳ Longevity & Aging, 🧠 Focus & Attention, ⚡ Energy & Fatigue. The primary research focus is 🔬 Oncology with 79% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Afatinib, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Loading evidence profile...

This evidence profile for Afatinib is generated deterministically from 297 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.